1. Home
  2. SNGX vs OMH Comparison

SNGX vs OMH Comparison

Compare SNGX & OMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • OMH
  • Stock Information
  • Founded
  • SNGX 1987
  • OMH 2015
  • Country
  • SNGX United States
  • OMH Singapore
  • Employees
  • SNGX N/A
  • OMH N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • OMH Real Estate
  • Sector
  • SNGX Health Care
  • OMH Finance
  • Exchange
  • SNGX Nasdaq
  • OMH Nasdaq
  • Market Cap
  • SNGX 7.4M
  • OMH 8.0M
  • IPO Year
  • SNGX 1987
  • OMH 2023
  • Fundamental
  • Price
  • SNGX $2.32
  • OMH $0.35
  • Analyst Decision
  • SNGX
  • OMH Strong Buy
  • Analyst Count
  • SNGX 0
  • OMH 1
  • Target Price
  • SNGX N/A
  • OMH $1.50
  • AVG Volume (30 Days)
  • SNGX 620.7K
  • OMH 123.1K
  • Earning Date
  • SNGX 03-14-2025
  • OMH 09-25-2024
  • Dividend Yield
  • SNGX N/A
  • OMH N/A
  • EPS Growth
  • SNGX N/A
  • OMH N/A
  • EPS
  • SNGX N/A
  • OMH N/A
  • Revenue
  • SNGX $364,183.00
  • OMH $5,390,607.00
  • Revenue This Year
  • SNGX N/A
  • OMH $101.90
  • Revenue Next Year
  • SNGX $76.64
  • OMH $38.34
  • P/E Ratio
  • SNGX N/A
  • OMH N/A
  • Revenue Growth
  • SNGX N/A
  • OMH 25.77
  • 52 Week Low
  • SNGX $0.32
  • OMH $0.32
  • 52 Week High
  • SNGX $14.83
  • OMH $6.00
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 36.12
  • OMH 47.46
  • Support Level
  • SNGX $2.23
  • OMH $0.34
  • Resistance Level
  • SNGX $2.39
  • OMH $0.37
  • Average True Range (ATR)
  • SNGX 0.17
  • OMH 0.02
  • MACD
  • SNGX 0.01
  • OMH 0.00
  • Stochastic Oscillator
  • SNGX 22.12
  • OMH 68.80

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About OMH Ohmyhome Limited

Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, Property Management Services, and revenue from emerging and other services.

Share on Social Networks: